See more

Mondaq's Must Reads

Trending This Week on Mondaq

Article
Counting Patents, Not Progress: Another Misdiagnosis By I-MAK
An April 2025 report from the Initiative for Medicines, Access & Knowledge (I-MAK) titled, "The Heavy Price of GLP-1 Drugs," presents grossly misleading information regarding the patent protection for semaglutide products (marketed by Novo Nordisk under the trademarks Ozempic, Rybelsus, and Wegovy) and tirzepatide products (marketed by Eli Lilly under the trademarks Mounjaro and Zepbound).
United States IP
FH
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
See more

Covers Donald Trump's Presidency, providing expert thought leadership across the various legal practice areas that may be impacted.

Including but not limited to Employment and HR, Immigration, International Law, Environment Law and Technology.

See more